Yebio latest Chinese firm to enter animal health industry's top 30
Qingdao Yibang Biological Engineering (Yebio) is the fourth Chinese business to feature in the animal health sector's top 30 rankings in terms of annual sales.
Animal Pharm has just published its latest report outlining the top 50 companies in the animal health space. Yebio has been included after Animal Pharm was able to ascertain the firm's animal health revenues for the first time.
Yebio specializes in veterinary biological products. Based in the coastal city of Qingdao, Yebio was established in 1999 through the privatization of the poultry disease research department of the China Animal Health and Epidemiology Center (CAHEC) – a national-level animal health research facility of China's Ministry of Agriculture.
Yebio's portfolio of animal health products comprises largely of vaccines for poultry and its management team stem mainly from CAHEC's center of research into poultry disease. CAHEC is still the controlling shareholder of the company and Yebio claims it inherits "the research character" of CAHEC.
Yebio operates two large-sized manufacturing and research hubs in Qingdao. It has six GMP workshops, a national-level facility developing genetically-engineered vaccines and a national-level testing laboratory. Yebio manufactures 80 different vaccines, and owns more than 30 new veterinary drug certificates, eight registered trademarks and has filed nearly 180 patents. Its portfolio of vaccines includes vaccines for Newcastle disease, La Sota disease, and avian influenza, both inactivated and activated, deliverable as single or combined vaccines.
Top 50 highlights modernizing industry
The new Animal Pharm Top 50 report also features several other companies that are appearing in the top 50 for the first time. It also features an in-depth overview of the different regional players that are ranked outside the top 50, including insight into the domestic leaders across Latin America.
The animal health industry is at something of a crossroads and on the cusp of a great modernization in terms of the way it approaches innovation.
As alternatives to antibiotics are sought and the humanization of pet care increases, the industry is being forced future-proof its business. The underlying growth trends in animal health are stimulating the top companies, which are focusing more on R&D and intelligent acquisitions. Naturally, a burgeoning industry has attracted investors.
As well as interest from financial backers, consumer scrutiny is at an all-time high for animal health companies. This is another trend that has shone a spotlight on the industry's leading players.
Innovation is underway in many different areas and power has swung away for the leading companies, who are tracking innovative start-ups much more closely.
The whole spectrum of the traditional 'animal health' sector is changing – led by this modernization and consumer advocacy. Realms such as diagnostics, nutrition and genetics are becoming much more relevant. This widening of the industry has seen the top firms start to take a broader approach to their portfolios to provide a wider portfolio of 'animal care' products.
The new Animal Pharm report takes a closer look at the companies behind the animal health industry. It not only provides an overview of how the firms are performing now but it also looks at the industry's past and future.
This is Animal Pharm's third report detailing the top 50 animal health companies in the world. This report features the aftermath of one of the biggest changes in the industry in recent times – the coming together of Boehringer Ingelheim Animal Health and Merial. This report also allows readers to track animal health's history of M&A, with many deals being the key reason the rankings change year-in year-out.
It is a global report, so it not only ranks North American and European firms, but also takes the best from Latin America and Asia into account.
The report not only highlights the trends influencing the current top 50 rankings but it delves into the Animal Pharm archives to analyze how the rankings have changed since 1990. It also highlights the ﬁrms outside of this year's rankings – companies that did not record enough revenues to make the ﬁnal cut (including pre-sales firms with significant candidate portfolios) and the businesses that did not disclose animal health earnings.
For more information about the report, visit the Animal Pharm report store.